The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
Fuente : http://www.eurekalert.org/pub_releases/2013-10/aaf...
Fuente : http://www.eurekalert.org/pub_releases/2013-10/aaf...